Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045784 | 1.00 | NOD1 (0.46) | NOD1SMN1; SMN2EPHX1ITGB3ITGA2B | |
| SCHEMBL3045780 | 1.00 | NOD1 (0.46) | NOD1SMN1; SMN2EPHX1ITGB3ITGA2B | |
| SCHEMBL10488527 | 0.98 | NOD1 (0.48) | NOD1SMN1; SMN2EPHX1FNTAFNTB | |
| SCHEMBL10488520 | 0.98 | NOD1 (0.48) | NOD1SMN1; SMN2EPHX1FNTAFNTB | |
| SCHEMBL13033691 | 0.98 | NOD1 (0.48) | NOD1SMN1; SMN2EPHX1FNTAFNTB | |
| SCHEMBL8573661 | 0.98 | NOD1 (0.48) | NOD1SMN1; SMN2EPHX1FNTAFNTB | |
| SCHEMBL10488513 | 0.98 | NOD1 (0.48) | NOD1SMN1; SMN2EPHX1FNTAFNTB | |
| SCHEMBL8573652 | 0.98 | NOD1 (0.48) | NOD1SMN1; SMN2EPHX1FNTAFNTB | |
| SCHEMBL7208125 | 0.92 | NOD1 (0.41) | NOD1SMN1; SMN2EPHX1ITGB3ITGA2B | |
| SCHEMBL4955824 | 0.86 | ITGB1 (0.38) | NOD1SMN1; SMN2CPB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3028696-B1 | AGENT FOR ALLEVIATING SIDE EFFECTS IN CANCER CHEMOTHERAPY | AJINOMOTO KK (JP) | 2021-01-27 | — | — | EP | claimed |
| US-7767714-B2 | Method of preventing infectious diseases | AJINOMOTO CO., INC. (JP) | 2010-08-03 | — | — | US | claimed |
| US-20080119551-A1 | SKIN COSMETICS COMPRISING A CYSTINE DERIVATIVE AND A CHEMICAL PEELING AGENT, A BACTERICIDE, AN ANIONIC SUFACTANT, OR A CATIONIC SURFACTANT | AJINOMOTO CO. INC (JP) | 2008-05-22 | — | — | US | claimed |
| US-20050079502-A1 | Transplant rejection suppressor | AJINOMOTO CO. INC. (JP) | 2005-04-14 | — | — | US | claimed |
| JP-4074116-A | — | — | None | — | — | JP | disclosed |
| JP-11302250-A | — | — | None | — | — | JP | disclosed |
| EP-2763658-B1 | TARGETED LIPOSOMES IN CANCER THERAPY | UNIV WESTERN HEALTH SCIENCES (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3028696-B1 | AGENT FOR ALLEVIATING SIDE EFFECTS IN CANCER CHEMOTHERAPY | AJINOMOTO KK (JP) | 2021-01-27 | — | — | EP | disclosed |
| US-10786471-B2 | Methods and products related to glutaminase inhibitors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-09-29 | — | — | US | disclosed |
| WO-2018145109-A1 | METHODS AND PRODUCTS RELATED TO GLUTAMINASE INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180221321-A1 | METHODS AND PRODUCTS RELATED TO GLUTAMINASE INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3028696-A1 | AGENT FOR ALLEVIATING SIDE EFFECTS IN CANCER CHEMOTHERAPY | Ajinomoto Co., Inc. (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-7767714-B2 | Method of preventing infectious diseases | AJINOMOTO CO., INC. (JP) | 2010-08-03 | — | — | US | disclosed |
| EP-1486208-B1 | USE OF A NOVEL PREVENTIVE FOR INFECTIONS | AJINOMOTO KK (JP) | 2006-09-27 | — | — | EP | disclosed |
| US-20050090511-A1 | Novel method of preventing infectious diseases | AJINOMOTO CO., INC. (JP) | 2005-04-28 | — | — | US | disclosed |
| US-20050079502-A1 | Transplant rejection suppressor | AJINOMOTO CO. INC. (JP) | 2005-04-14 | — | — | US | disclosed |
| JP-2005060360-A | OPHTHALMIC MEDICINE | YAMADA JUN | 2005-03-10 | — | — | JP | disclosed |
| EP-1486208-A1 | NOVEL PREVENTIVE FOR INFECTIONS | Ajinomoto Co., Inc. (JP) | 2004-12-15 | — | — | EP | disclosed |
| JP-H11302250-A | PRODUCTION OF N,N'-DIACYLCYSTINE DERIVATIVE | NAMIKI SHOJI KK | 1999-11-02 | — | — | JP | disclosed |
| JP-H0474116-A | LIPOSOME | AGENCY OF IND SCIENCE & TECHNOL | 1992-03-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221321-A1 | METHODS AND PRODUCTS RELATED TO GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | NOD1 4655/4885SMN1; SMN2 3913/4885EPHX1 1776/4885 |
| US-20080119551-A1 | SKIN COSMETICS COMPRISING A CYSTINE DERIVATIVE AND A CHEMICAL PEELING AGENT, A BACTERICIDE, AN ANIONIC SUFACTANT, OR A CATIONIC SURFACTANT | CUTA, CTH, SRM | NOD1 3602/4885SMN1; SMN2 4515/4885EPHX1 2402/4885 |
| US-10786471-B2 | Methods and products related to glutaminase inhibitors | GLS, GLS2, GLUL | NOD1 4655/4885SMN1; SMN2 3913/4885EPHX1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.